This dataset includes detailed information for 22,016 individuals. by Yeo Ju Sohn (18536198)

Subjects:

Flow diagram of participants meeting the inclusion and exclusion criteria. by Yeo Ju Sohn (18536198)

Subjects:

Initial participants by wave*. by Yeo Ju Sohn (18536198)

Subjects:

These files contain the STATA program codes used in the study. by Yeo Ju Sohn (18536198)

Subjects:

Generalized estimating equation model covariance structure analysis. by Yeo Ju Sohn (18536198)

Subjects:

Raw dataset collected from the KLoSA from 2006 to 2020. by Yeo Ju Sohn (18536198)

Subjects:

General characteristics of research participants. by Yeo Ju Sohn (18536198)

Subjects:

Generalized estimation equation model analysis of diabetes mellitus incidence according to relative handgrip strength. by Yeo Ju Sohn (18536198)

Subjects:

Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength. by Yeo Ju Sohn (18536198)

Subjects:

Genomic downregulation of TGF β1 production in monocytes obtained after RZV administration. Panel A. The heatmap shows 16 genes on the y axis whose accessibility significantly chan... by Michael J. Johnson (5818168)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Risk factors for <i>Schistosoma haematobium</i> infection. by Lydia Trippler (10136316)

Subjects:

S1 Data - Adaptive integrated intervention approaches for schistosomiasis elimination in Pemba: A 4-year intervention study and focus on hotspots by Lydia Trippler (10136316)

Subjects:

Demographic information of study participants. Demographic information of participants in school-based and household-based cross-sectional surveys of the SchistoBreak study impleme... by Lydia Trippler (10136316)

Subjects:

S2 Data - Adaptive integrated intervention approaches for schistosomiasis elimination in Pemba: A 4-year intervention study and focus on hotspots by Lydia Trippler (10136316)

Subjects:

Characteristics of households participating in the SchistoBreak study in Pemba, Tanzania. by Lydia Trippler (10136316)

Subjects:

<i>Schistosoma haematobium</i> and microhematuria prevalence. by Lydia Trippler (10136316)

Subjects:

Chance of infection with <i>Schistosoma haematobium.</i> by Lydia Trippler (10136316)

Subjects: